JG
TBPH icon

Jefferies Group’s Theravance Biopharma TBPH Stock Holding History

Jefferies Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-390,000
Closed -$6.37M – 3033
2019
Q2 		$6.37M Buy
390,000
+130,000
+50% +$2.63M 0.05% 369
2019
Q1 		$5.89M Buy
+260,000
New +$6.59M 0.05% 378

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jefferies Group's TBPH Position: Q2 2021 in Review

Jefferies Group sold out of Theravance Biopharma (TBPH) in Q2 2021, closing a stake of 12,414 shares — an estimated $253K sold.

Jefferies Group first reported a position in TBPH in Q1 2019 and held it in 3 quarters. The position peaked at $5.02M in Q2 2019. 108 funds tracked by Wall St. Rank hold TBPH as of Q2 2021.

  • Jefferies Group reported no remaining Theravance Biopharma position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 12,414 Theravance Biopharma shares in Q2 2021, an estimated $253K.
  • Jefferies Group first reported a position in Theravance Biopharma in Q1 2019 and held it in 3 quarters.
  • Jefferies Group's Theravance Biopharma position peaked at $5.02M in Q2 2019.
  • 108 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.